Results from a new study published in the American Heart Association’s Hypertension showed that the GLP-1, tirzepatide, reduced 24-hour systolic BP, both at night and in the daytime compared with placebo.

Patients paid less money out of pocket for naloxone from 2018 through 2022, according to a new analysis published in JAMA. The research, which was based on data from the IQVIA Longitudinal Prescription database, revealed that the mean out-of-pocket cost per prescription declined from $22.51 in 2018 to $10.02 in 2022.

A global increase in severe antimicrobial-resistant fungal infections of the skin—partly due to inappropriate use of topical antifungals and antifungal-corticosteroid combinations—has found its way to the United States.